Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Poluzzi

Showing results (41-50 of 189) with videos related to

Pageof 19
Sort By:
British Journal of Clinical Pharmacology|July 23, 2011
QT interval shortening in spontaneous reports submitted to the FDA: the need for consensusEmanuel Raschi, Elisabetta Poluzzi, Ariola Koci, et al.
Medicinal Research Reviews|September 25, 2004
QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug developmentMaurizio Recanatini, Elisabetta Poluzzi, Matteo Masetti, et al.
British Journal of Anaesthesia|October 30, 2025
Contemporary local anaesthetic-associated adverse events and mortality: searching for the root causes of the pharmacovigilance signal. Br J Anaesth 2026;136:411-13Emanuel Raschi, Tommaso Tonetti, Charles Khouri, et al.
Drug Safety|May 8, 2002
Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overviewFabrizio De Ponti, Elisabetta Poluzzi, Andrea Cavalli, et al.
World Journal of Hepatology|September 19, 2014
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS databaseEmanuel Raschi, Elisabetta Poluzzi, Ariola Koci, et al.
Frontiers in Pharmacology|December 27, 2021
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting SystemMichele Fusaroli, Emanuel Raschi, Milo Gatti, et al.
Expert Opinion on Pharmacotherapy|November 3, 2020
SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?Emanuel Raschi, Gian Paolo Fadini, Igor Diemberger, et al.
Diabetes, Obesity & Metabolism|July 14, 2018
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?Emanuel Raschi, Elisabetta Poluzzi, Gian Paolo Fadini, et al.
Addiction (Abingdon, England)|November 12, 2022
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the 'impulse control disorders' diagnostic constructMichele Fusaroli, Luca Pellegrini, Riccardo Fusaroli, et al.
Vaccines|January 7, 2021
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBaseMilo Gatti, Emanuel Raschi, Ugo Moretti, et al.
Pageof 19

Showing results (41-50 of 189) with videos related to

Sort By:
Pageof 19
British Journal of Clinical Pharmacology|July 23, 2011
QT interval shortening in spontaneous reports submitted to the FDA: the need for consensusEmanuel Raschi, Elisabetta Poluzzi, Ariola Koci, et al.
Medicinal Research Reviews|September 25, 2004
QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug developmentMaurizio Recanatini, Elisabetta Poluzzi, Matteo Masetti, et al.
British Journal of Anaesthesia|October 30, 2025
Contemporary local anaesthetic-associated adverse events and mortality: searching for the root causes of the pharmacovigilance signal. Br J Anaesth 2026;136:411-13Emanuel Raschi, Tommaso Tonetti, Charles Khouri, et al.
Drug Safety|May 8, 2002
Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overviewFabrizio De Ponti, Elisabetta Poluzzi, Andrea Cavalli, et al.
World Journal of Hepatology|September 19, 2014
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS databaseEmanuel Raschi, Elisabetta Poluzzi, Ariola Koci, et al.
Frontiers in Pharmacology|December 27, 2021
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting SystemMichele Fusaroli, Emanuel Raschi, Milo Gatti, et al.
Expert Opinion on Pharmacotherapy|November 3, 2020
SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?Emanuel Raschi, Gian Paolo Fadini, Igor Diemberger, et al.
Diabetes, Obesity & Metabolism|July 14, 2018
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?Emanuel Raschi, Elisabetta Poluzzi, Gian Paolo Fadini, et al.
Addiction (Abingdon, England)|November 12, 2022
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the 'impulse control disorders' diagnostic constructMichele Fusaroli, Luca Pellegrini, Riccardo Fusaroli, et al.
Vaccines|January 7, 2021
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBaseMilo Gatti, Emanuel Raschi, Ugo Moretti, et al.
Pageof 19